Literature DB >> 16705507

Photodynamic therapy in the treatment of chronic central serous chorioretinopathy.

C Valmaggia1, H Niederberger.   

Abstract

BACKGROUND: Central serous chorioretinopathy (CSC) is usually a benign disorder which resolves spontaneously, and requires no treatment. Nevertheless, in cases of chronic or recurrent detachment of the neurosensory retina a durable decrease of the visual acuity may be measured due to lesion of the photoreceptors. To avoid this evolution we performed a pilot study to assess the effect of photodynamic therapy (PDT) in patients with CSC without clinical normalization 6 months after the begin of the symptoms. PATIENTS AND METHODS: We report on 14 eyes in 13 patients presenting a chronic CSC without leaking point accessible for focal laser photocoagulation. The diagnosis was confirmed by fluorescein angiography (FA), and optical coherence tomography (OCT). PDT with verteporfin was performed according to the protocol used for treating choroidal neovascularization in age-related macular degeneration.
RESULTS: One month after PDT, leakage on FA and detachment of the neurosensory retina on OCT had disappeared, and visual acuity had improved in all patients.
CONCLUSIONS: The mechanism of action of PDT in chronic CSC is still hypothetical. PDT should decrease the passage of fluid towards the retina by affecting the choroidal blood flow, and allow a better resorption of the subretinal fluid. PDT could be an alternative to treat patients with chronic CSC.

Entities:  

Mesh:

Year:  2006        PMID: 16705507     DOI: 10.1055/s-2006-926567

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  4 in total

1.  Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy.

Authors:  Sergio Copete; Jose M Ruiz-Moreno; Carlos Cava; Javier A Montero
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-06       Impact factor: 3.117

2.  [Therapy options for chronic central serous chorioretinopathy. Photodynamic therapy combined with bevacizumab - a case series].

Authors:  M Maier; V Valet; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2011-11       Impact factor: 1.059

3.  Photodynamic therapy rescue for subretinal fluid exacerbation after focal laser treatment in idiopathic central serous chorioretinopathy.

Authors:  Theodore Leng; Steven R Sanislo; Robert L Jack
Journal:  Open Ophthalmol J       Date:  2011-01-18

4.  Photodynamic therapy and central serous chorioretinopathy.

Authors:  Lina Siaudvytyte; Vaida Diliene; Goda Miniauskiene; Vilma Jurate Balciuniene
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2012
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.